

NIH Public Access

Author Manuscript

Pancreas. Author manuscript; available in PMC 2009 August 1.

Published in final edited form as:

Pancreas. 2008 August ; 37(2): 182-188. doi:10.1097/MPA.0b013e3181663066.

The guinea pig pancreas secretes a single trypsinogen isoform, which is defective in autoactivation

Béla Ózsvári, M.S.,

Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, Boston, Massachusetts; and 1st Department of Medicine, University of Szeged, Faculty of Medicine, Szeged, Hungary.

Péter Hegyi, M.D., Ph.D., and

1st Department of Medicine, University of Szeged, Faculty of Medicine, Szeged, Hungary.

Miklós Sahin-Tóth, M.D., Ph.D.

Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, Boston, Massachusetts.

Abstract

Objectives—The aim of the present study was to purify and clone the trypsinogen isoforms from the guinea pig pancreas and characterize their activation properties.

Methods—Trypsinogens from pancreatic homogenates were isolated by ecotin-affinity chromatography, followed by cation-exchange chromatography. Activation of trypsinogens was tested with enteropeptidase, cathepsin B and trypsin. Complementary DNAs for pre-trypsinogens were cloned from total RNA after reverse transcription and PCR-amplification.

Results—Purification of trypsinogens yielded a single peak with an N-terminal amino-acid sequence of LPIDD. Cloning of pre-trypsinogen cDNAs revealed two distinct but nearly identical isoforms. At the amino acid level, the only difference between the two isoforms is an Ala/Ser change at position 15 within the signal peptide. Thus, both cDNA variants give rise to the same mature trypsinogen upon secretion. Guinea pig trypsinogen is readily activated by enteropeptidase and cathepsin B, but exhibits essentially no autoactivation, under conditions where human cationic and anionic trypsinogens rapidly autoactivate.

Conclusions—The observations suggest that multiple trypsinogen isoforms and their ability to autoactivate are not required universally for normal digestive physiology in mammals. Furthermore, the inability of guinea pig trypsinogen to undergo autoactivation suggests that this species might be more resistant to pancreatitis than humans, where increased autoactivation of cationic trypsinogen mutants has been linked to hereditary pancreatitis.

Keywords

zymogen activation; enteropeptidase; cathepsin B; autoactivation; trypsinogen isoforms; ecotin

INTRODUCTION

The guinea pig pancreas is a classic model of exocrine glands, which was used to elucidate the basic principles of regulated enzyme secretion (e.g. 1,2). More recently, the guinea pig pancreas

Address correspondence to: Miklós Sahin-Tóth; Boston University Medical Center; 715 Albany Street, Evans-433; Boston, MA 02118. Telephone: 1-617-414-1070; Fax: 1-617-414-1041; E-mail: miklos@bu.edu.

has gained popularity as a model system for the study of transport processes of the excretory duct system (3,4). Although early studies using one or two-dimensional gel electrophoresis identified a trypsinogen in the guinea pig pancreas (5,6), the number of isoforms and their amino-acid or cDNA sequence has not been determined. Furthermore, activation of guinea pig trypsinogens and activity of guinea pig trypsins has never been studied either.

Trypsin plays an important initiator role in experimental acute pancreatitis. A number of animal models of acute pancreatitis have been established, which include the secretagouge-induced edematous (7), the L-arginine-induced necrotizing (8–10), and the bile acid-induced necrotizing and hemorrhagic (11,12) types. These models are well-characterized in the rat and mouse, however, only a few studies utilized guinea pigs (13,14).

Trypsin also contributes to the pathogenesis of chronic pancreatitis in humans. The human pancreas expresses three isoforms of trypsinogen, commonly referred to as cationic trypsinogen, anionic trypsinogen and mesotrypsinogen. These isoenzymes are encoded by separate genes, the *PRSS1* (protease, serine, 1), *PRSS2* and *PRSS3* genes (15). Relatively recent genetic studies identified several variants in the *PRSS1* gene that are associated with hereditary or sporadic idiopathic chronic pancreatitis (16,17). The majority of the disease-causing *PRSS1* variants stimulate autoactivation of cationic trypsinogen *in vitro* and most likely cause premature intrapancreatic trypsin activation *in vivo* (17). Variants in the *PRSS2* or *PRSS3* genes have not been found in association with chronic pancreatitis, however, the recently identified p.G191R *PRSS2* variant, which undergoes rapid autodegradation, was shown to protect against chronic pancreatitis (18). The central role of trypsin in pancreatitis pathogenesis is also underscored by the finding that loss-of-function mutations in the *SPINK1* gene, that encodes the physiological inhibitor of trypsin, are also associated with chronic pancreatitis (19). Furthermore, loss-of-function mutations in the trypsin-degrading enzyme chymotrypsin C (*CTRC*) were found in association with chronic pancreatitis (20).

Here we report the cDNA cloning and purification of trypsinogen from the guinea pig pancreas. We found that the guinea pig pancreas secretes a single major trypsinogen isoform, which is encoded by two distinct mRNA species. Surprisingly, autoactivation of the guinea pig trypsinogen was minimal, suggesting that autoactivation is relatively unimportant for physiological zymogen activation in this species. The lack of autoactivation also suggests that this species might be less prone to the development of pancreatitis.

MATERIALS AND METHODS

Materials

Whole pancreata from Abyssinian guinea pigs were purchased from Rockland Immunochemicals (Gilbertsville, PA). The pancreata were flash frozen in liquid nitrogen, shipped on dry ice and stored at -80 °C. RNAqueousTM Phenol-free total RNA Isolation kit was from Ambion Inc. (Austin, TX), SMARTTM RACE cDNA Amplification Kit from Clontech Laboratories Inc. (Mountain View, CA), Zero Blunt TOPO PCR Cloning Kit from Invitrogen Corp. (Carlsbad, CA) and *N*-CBZ-Gly-Pro-Arg-*p*-nitroanilide from Sigma-Aldrich (St. Louis, MO). Human trypsinogens were expressed in *Escherichia coli* and affinity-purified as described previously (21–24). Recombinant human pro-enteropeptidase was from R&D Systems (Minneapolis, MN). Human pro-enteropeptidase (0.07 mg/mL stock solution) was activated with 50 nM human cationic trypsin in 0.1 M Tris-HCl (pH 8.0), 10 mM CaCl₂ and 2 mg/ml bovine serum albumin (final concentrations) for 30 min at room temperature. Human recombinant cathepsin B was a generous gift from Paul M. Steed (Research Department, Novartis Pharmaceuticals, Summit, New Jersey). Before use, cathepsin B was activated with 1 mM dithiothreitol (final concentration) for 30 min on ice.

Purification of trypsinogen

Guinea pig pancreatic tissue (5 g) was homogenized in 0.1 M Tris-HCl, pH 8.0 using a rotorstator tissue homogenizer (T 25, IKA Works) at 11,000 – 13,000 rpm and the homogenate was centrifuged for 8 min at 13,000 rpm, at 4 °C. The supernatant was further clarified by a second round of centrifugation, and then loaded onto a 2 mL ecotin-affinity column. The column was washed with 20 mM Tris–HCl (pH 8.0), 0.2 M NaCl and elution was performed with 50 mM HCl. The ecotin-eluate (~1 mg protein in 3–4 mL volume) was directly loaded onto a Mono S HR 5/5 strong cation-exchange column equilibrated with 20 mM Na-acetate (pH 5.0). The Mono S column was developed with a linear gradient of 0–0.5 M NaCl. Concentrations of guinea pig trypsinogen preparations were estimated from UV absorbance at 280 nm, using a theoretical extinction coefficient of 37,650 M^{-1} cm⁻¹ (http://ca.expasy.org/tools/protparam.html).

Complementary DNA cloning

Total RNA isolation was performed from 30 mg homogenized guinea pig pancreas by the RNAqueousTM Phenol-free total RNA Isolation kit modified with an additional phenolchloroform extraction. First-strand cDNA was synthesized using the SMART[™] RACE cDNA Amplification Kit with 2 µg RNA. For the 5' RACE reaction, first-strand synthesis was primed with an oligo(dT) primer. The reverse transcriptase used in the reaction exhibits terminal transferase activity and adds a series of dC residues to the 3' end of the cDNA. An oligonucleotide (SMART IIA) present in the reaction mixture anneals to the dC stretch and serves as template for further extension of the cDNA. The end result of the reaction is a full length cDNA with an additional SMART sequence at the 5' end. For the 3' RACE, the mRNA is reverse transcribed with an oligo(dT) primer which anneals to the polyA tail and also incorporates the SMART sequence at its 5' end. Guinea pig trypsinogen cDNA was PCRamplified in 2 reactions from the first-strand 5' and 3' RACE cDNAs using a gene-specific primer and a Universal primer that annealed against the SMART sequence incorporated into the first-strand cDNA either at the 5' or 3' ends. The gene specific GP1 primers annealed with relatively low stringency to the region around the conserved catalytic Ser200 (see Fig 1); the GP1 sense primer (5'-TGT CAG GGA GAC TCT GGT GGC CCA GTT GTC TGC-3') corresponded to codons 196-206, and the GP1 antisense primer (5'-GCA GAC AAC TGG GCC ACC AGA GTC TCC CTG-3') corresponded to codons 197-206 (Fig 1). These primers were previously designed against the corresponding region of the Bothrops jararaca trypsinogen (GenBank #AF190273) and used successfully in other cloning projects in our laboratory. PCR products were purified and directly subcloned into the pCR-Blunt II-TOPO vector using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen). Fifteen clones from the 5' RACE reaction and 3 clones from the 3' RACE reaction were sequenced. The initial sequence information indicated that 2 almost identical cDNA species were cloned. On the basis of the initial sequencing results, new trypsinogen-specific primers were designed. The GP2 sense primer (5'- AGC TAC AGC AGC AGC ACC CTG AAC -3') anneals to codons 98-105, and the GP2 antisense primer (5'- GAT CTG TCC AGG ATA GGC GGA CTG -3') anneals to codons 172-179 (Fig 1). Using the GP2 primers and the Universal primer additional trypsinogen-specific amplicons were generated from the first-strand 5' RACE and 3' RACE cDNA and subcloned into the pCR-Blunt II-TOPO vector. Five clones from the 5' RACE reaction and 4 clones from the 3' RACE reaction were sequenced. Finally, the full length cDNA sequences of the 2 guinea pig pre-trypsinogen isoforms were reconstructed from overlapping fragments. The guinea pig pre-trypsinogen cDNA sequences have been deposited to GenBank under accession numbers EF371801 and EF371802.

Assay of trypsin activity

Trypsin activity was determined using the synthetic chromogenic substrate *N*-CBZ-Gly-Pro-Arg-*p*-nitroanilide. Kinetics of the chromophore release was followed at 405 nm in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl₂, at 22 °C using a Spectramax Plus 384 microplate reader (Molecular Devices Corp.).

Trypsinogen activation with enteropeptidase

 $2 \mu M$ (final concentration) trypsinogen was incubated with 28 ng/mL human enteropeptidase holoenzyme (final concentration) at 37 °C, in 0.1 M Tris-HCl, pH 8.0, 2 mg/mL bovine serum albumin and 1 mM CaCl₂ in a final volume of 100 μ L. Aliquots of 2 μ L were withdrawn from reaction mixtures at the indicated times, and trypsin activity was determined with the synthetic substrate *N*-CBZ-Gly-Pro-Arg-*p*-nitroanilide.

Trypsinogen activation with human cathepsin B

Trypsinogens were activated at 2 μ M concentration with human cathepsin B (90 μ g/mL final concentration) at 37 °C in 0.1 M Na-acetate buffer (pH 4.0) in the presence of 1 mM dithiothreitol, 2 mg/mL bovine serum albumin, 1 mM K-EDTA, and 0.3 mM benzamidine; as described previously (25). Aliquots (2 μ L) were withdrawn at indicated times and trypsin activity was measured on the synthetic substrate.

Trypsinogen autoactivation

Trypsin-mediated trypsinogen activation was measured at 37 °C, using 2 μ M trypsinogen, 1 mM CaCl₂, 0.1 M Tris-HCl (pH 8.0), 2 mg/mL bovine serum albumin and 200 nM trypsin initial concentrations.

Trypsin autolysis

Trypsinogens (final concentration 2 μ M) were activated to trypsin with enteropeptidase for 60 min at 37 °C in the presence of 1 mM CaCl₂. Autocatalytic inactivation of trypsins was then followed at 37 °C after addition of K-EDTA (pH 8.0) to a final concentration of 2 mM. At indicated time points aliquots (2 μ L) were withdrawn and residual trypsin activity was measured on the synthetic substrate.

RESULTS

Purification of guinea pig trypsinogens

Tissue extracts from the guinea pig pancreas were applied to an ecotin-affinity column (26). Ecotin is a pan-serine-protease inhibitor, which binds to pancreatic serine proteases (trypsins, chymotrypsins, elastases) and their zymogen forms. The flow-through of the ecotin-column was analyzed for the presence of trypsin activity after activation with enteropeptidase. The complete absence of trypsin activity indicated that all trypsinogen isoforms were bound to the ecotin column. Elution was performed under acidic conditions, and SDS-PAGE analysis revealed two closely migrating bands, a lighter upper band and a strong lower band, indicating that at least 2 different proteins were present in the ecotin eluate (Fig 2). To resolve these proteins, the ecotin eluate was loaded onto a Mono S cation-exchange column equilibrated with 20 mM Na-acetate (pH 5.0) and eluted with a NaCl gradient (0-0.5 M). A single major peak was eluted at approximately 0.15 M NaCl concentration (Fig 2A), which was identified as trypsinogen on the basis of its enzymatic activity after activation with enteropeptidase. In addition, a small, broader peak was eluted at approximately 0.22 M NaCl, which exhibited both trypsin and chymotrypsin activity upon activation with enteropeptidase or trypsin, respectively. Although not shown, the number of peaks eluted did not change when the NaCl gradient was extended to 1.0 M. Aliquots of fractions were analyzed by SDS-PAGE and

Coomassie blue staining. The first, main peak showed only a single band, whereas the second peak contained two bands, one of which co-migrated with the trypsinogen band recovered in the first peak (Fig 2B). N-terminal sequencing of the first, major trypsinogen peak revealed a single, homogeneous sequence of Leu-Pro-Ile-Asp-Asp, suggesting that this peak contains a single trypsinogen isoform. This trypsinogen isoform was novel, as the N-terminal sequence determined was distinct from the known trypsinogen sequences found in protein databases. The second peak contained a mixture of two different N-terminal sequences, a trypsinogen N terminus identical to the one found in the first, major peak and a chymotrypsinogen-like N terminal sequence of Cys-Gly-Val-Pro-Ala. Therefore, the enzyme activity assays and N

terminal sequencing are in agreement demonstrating that the smaller Mono S peak contains a mixture of a trypsinogen and a chymotrypsinogen. The identical N-terminal sequences of the trypsinogens recovered in the first and second peaks suggested that the two peaks contained the same isoform and the small second trypsinogen peak represented an oligomeric or aggregate form of guinea pig trypsinogen. This conclusion was also supported by comparative MS/MS peptide sequencing of trypsinogens from the two peaks (see below).

Complementary DNA cloning of guinea pig trypsinogens

To determine the complete cDNA sequence of the guinea pig trypsinogen(s), we utilized a PCR-based cloning method after 5' and 3' RACE, as described in Experimental Procedures. The assembled cDNA sequences were essentially identical with the exception of 2 positions (Fig 1). Thus, at c.43 (in codon 15) a G/T variation was observed, whereas at c.276 (in codon 92) an A/G variation was found. The variant with c.43G and c.276A was arbitrarily designated as isoform 1 and the variant with c.43T and c.276G as isoform 2. The sequences of the 2 isoforms have been deposited with GenBank under accession numbers EF371801 and EF371802. The relative amounts of the two isoforms at the mRNA level appeared to be comparable, as judged from the isoform distribution of the sequenced 5' RACE clones. The G/ T variation at codon 15 affects the encoded amino acid, which is predicted either as Ala (GCC) or Ser (TCC). In contrast, the G/A variation at position 92 has no affect at the protein level as both AAG and AAA codons encode Lys. Therefore, the deduced amino-acid sequences of the 2 isoforms differ only in amino-acid 15, which is either Ala or Ser. Position 15 is the last amino-acid of the secretory signal peptide, which is removed upon entry into the endoplasmic reticulum. The mature trypsinogens resulting from the two variants are thus identical, and the guinea pig pancreas secretes a single trypsinogen isoform.

The guinea pig pre-trypsinogens are composed of 246 amino acid residues, and the 231 aminoacid long mature trypsinogen has a predicted molecular weight of 24,378.5 Da. The guinea pig trypsinogen is cationic in character, with a theoretical pI value of 8.0 (http://ca.expasy.org/tools/protparam.html). The N-terminal 15 amino acids form the signal peptide, which is followed by the 8 amino-acid long trypsinogen activation peptide including the highly conserved tetra-aspartate motif (Fig 1). Importantly, the predicted and experimentally determined N-terminal sequences of guinea pig trypsinogen are in perfect agreement. The molecule is stabilized by 6 disulfide bridges, characteristic of most vertebrate trypsinogens. Acidic determinants of the calcium-binding loop are also fully conserved (Glu75, Glu82 and Glu85). Similarly to human mesotrypsinogen, position 79 is Lys in the guinea pig trypsinogen, instead of the more typical Glu found in other mammalian trypsinogens. The functional role of this side-chain is unclear, but the Glu79→Lys mutation (E79K) in human cationic trypsinogen seems to be associated with chronic pancreatitis (27). It is interesting to note that the otherwise highly conserved Arg122 is replaced with a Lys in the guinea pig trypsinogen. Arg122 is a trypsin sensitive site, which is believed to be important for autocatalytic degradation of bovine, rat and human trypsins (28,29). Mutation of Arg122 to His causes hereditary chronic pancreatitis in humans (16). Relative to human trypsinogens, there is a low ratio of charged side-chains in the guinea pig trypsinogen (Arg, Lys, Asp and

Glu residues; 11.3 % in guinea pig trypsinogen versus 18.1 % in both human trypsinogens), and a higher abundance of Ser residues (14.3 % in guinea pig trypsinogen versus 8.6 % and 10.3 % in human cationic and anionic trypsinogens, respectively). The guinea pig trypsinogen exhibits the strongest similarity to the bovine cationic trypsinogen (82 % identity), whereas the identity with human cationic and anionic trypsinogens are 76 % and 75 %, respectively.

MS/MS peptide sequencing of purified guinea pig trypsinogen

To obtain independent sequence information from the purified guinea pig trypsinogen, a sample was subjected to tandem MS peptide sequencing. After electrophoresis on a 15 % SDS-PAGE, the trypsinogen band was excised and digested in-gel with sequencing grade modified porcine trypsin (Promega Corp., Madison, WI). The resulting peptide mixture was then analyzed by LC-MS/MS (ProtTech, Inc.; Eagleville, PA). The following tryptic peptides were sequenced. LPIDDDDK (from Leu16 to Lys23); VSEGSEQFITASK (from Val80 to Lys92); HPSYSSSTLNNDIMLIK (from His96 to Lys112); and LASAANLNSK (from Leu113 to Lys122). Although this approach yielded only about 20 % coverage of the protein sequence; the peptides sequenced were in perfect agreement with the amino-acid sequence predicted from the cloned cDNA. The trypsinogen band from the small, second Mono S peak was also subjected to MS/MS analysis and the exact same tryptic fragments were identified, confirming that this peak contained the same isoform of trypsinogen as the first, main Mono S peak.

Activation of guinea pig trypsinogen

Activation characteristics and catalytic properties of guinea pig trypsinogen were compared to those of human anionic and cationic trypsinogens, which comprise 90–95 % of trypsinogens in humans. The physiological activator enteropeptidase readily activated guinea pig trypsinogen at pH 8.0, although at a rate that was slower than activation of human cationic trypsinogen (Fig 3). Similarly, activation of guinea pig trypsinogen by the pathological activator cathepsin B at pH 4.0 was slower, but still significant, relative to human cationic trypsinogen (Fig 4). Because we used human enteropeptidase and cathepsin B preparations in our experiments, the observed differences in activation rates between the human and guinea pig trypsinogens should be interpreted cautiously. The important conclusion of the experiments in Fig 3 and Fig 4 is that both enteropeptidase and cathepsin B can activate guinea pig trypsinogen under certain conditions.

In contrast, a completely different picture emerged when autoactivation of guinea pig trypsinogens and human trypsinogens were compared. Human anionic and cationic trypsinogens autoactivated rapidly, whereas guinea pig trypsinogen exhibited essentially no autoactivation (Fig 5).

Catalytic activity and autolysis of guinea pig trypsin

Catalytic parameters of guinea pig trypsin were determined on the peptide substrate N-CBZ-Gly-Pro-Arg-p-nitroanilide. The k_{cat} and K_M values were similar to those of human trypsins, indicating that lack of autoactivation (see above) was not due to a catalytic defect in guinea pig trypsin (Table 1).

Autocatalytic degradation (autolysis) of guinea pig trypsin was also measured. Fig 6 demonstrates that at pH 8.0, in the absence of Ca^{2+} , the guinea pig trypsin underwent relatively slow autolysis at an intermediate rate between those of the two human trypsins. As observed previously, human cationic trypsin was resistant to autolysis, whereas anionic trypsin rapidly autodegraded (22–24,30,31).

DISCUSSION

The present study offers two interesting observations for discussion. First, the guinea pig pancreas secretes a single major trypsinogen isoform, which is somewhat atypical, as most vertebrate species express multiple trypsinogen isoforms. Second, compared to the human trypsinogens, the guinea pig trypsinogen is defective in autoactivation.

The trypsinogen genes are intercalated between the beta T-cell receptor genes in humans, the mouse and the chicken (32–35). This unusual location might explain the tendency of the trypsinogen genes to undergo significant rearrangements during speciation, which includes duplications with the formation of new genes and pseudogenes as well as gene losses. All species sequenced to date contain multiple trypsinogen genes in their genome, of which only a limited number are expressed at the protein level (36). In humans, 9 genomic trypsinogen sequences were identified, but only 3 isoforms are expressed to measurable protein levels (13). The mouse genome contains 20 trypsinogen genes, but the normal mouse pancreas secretes only 4 trypsinogen isoforms (M. S.-T., unpublished data). The finding that the guinea pig pancreas secretes a single major isoform indicates that multiple isoforms are not an obligatory requirement for digestion, but they probably confer species-specific adaptive advantages. The guinea pig genome has not been sequenced yet, but it is very likely that it also contains multiple trypsinogen genes. This assumption is supported by the cloning of the 2 nearly identical cDNA forms, indicating the presence of at least 2 recently duplicated genes.

Although we posit that the guinea pig pancreas expresses 2 different mRNAs for pretrypsinogen, which result in the expression of a single mature trypsinogen, there are caveats to this conclusion. First, the biochemical approach utilized here may not detect isoforms present in low quantities (1 % or less of total trypsinogens). Second, the cDNA cloning approach used may not identify isoforms in which the cDNA sequence around the catalytic Ser is less conserved, or isoforms present in very low amounts. Finally, hormonal stimulation of the pancreas may result in the expression of additional trypsinogen isoforms, which have not been found in this study.

Autoactivation of trypsinogen is believed to facilitate physiological zymogen activation in the duodenum. During autoactivation trypsin activates trypsinogen to trypsin, resulting in a self-amplifying reaction. Mutations in the human cationic trypsinogen that cause acceleration of autoactivation *in vitro* have been associated with hereditary pancreatitis, suggesting that autoactivation may be important for premature trypsinogen activation during pancreatitis, at least in humans (16,17). The inability of the guinea pig trypsinogen to autoactivate indicates that this mode of trypsinogen activation observed with the human trypsinogens may indicate a positive evolutionary selection. The relatively high abundance of surface exposed charged side chains (Glu, Asp, Lys, Arg) in the human trypsinogens and their absence in the guinea pig trypsinogen suggests that efficient autoactivation requires interactions associated with these strongly polar amino acids. Finally, the inability of the guinea pig trypsinogen to undergo autoactivation also suggests that this species might be more resistant to the development of pancreatitis, which would explain the scarcity of experimental models of acute pancreatitis using the guinea pig (13,14).

Acknowledgments

This work was supported by NIH grant DK058088 to M. S.-T and a scholarship from the Rosztoczy Foundation to B. O.

REFERENCES

- 1. Scheele GA, Palade GE. Studies on the guinea pig pancreas. Parallel discharge of exocrine enzyme activities. J Biol Chem 1975;250:2660–2670. [PubMed: 1123325]
- Tartakoff AM, Jamieson JD, Scheele GA, et al. Studies on the pancreas of the guinea pig. Parallel processing and discharge of exocrine proteins. J Biol Chem 1975;250:2671–2677. [PubMed: 1123326]
- Case, RM.; Argent, BE. Pancreatic duct secretion: control and mechanisms of transport. In: Go, VLW.; DiMagno, EP., et al., editors. The Pancreas: Biology, Pathobiology, and Disease. New York: Raven Press; 1993. p. 301-350.
- Hegyi P, Rakonczay Z Jr. The inhibitory pathways of pancreatic ductal bicarbonate secretion. Int J Biochem Cell Biol 2007;39:25–30. [PubMed: 16996776]
- Tartakoff A, Greene LJ, Palade GE. Studies on the guinea pig pancreas. Fractionation and partial characterization of exocrine proteins. J Biol Chem 1974;249:7420–7431. [PubMed: 4436317]
- Scheele GA. Two-dimensional gel analysis of soluble proteins. Charaterization of guinea pig exocrine pancreatic proteins. J Biol Chem 1975;250:5375–5385. [PubMed: 1141235]
- 7. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol 1977;373:97–117. [PubMed: 139754]
- Mizunuma T, Kawamura S, Kishino Y. Effects of injecting excess arginine on rat pancreas. J Nutr 1984;114:467–471. [PubMed: 6199486]
- Hegyi P, Rakonczay Z Jr, Sari R, et al. L-arginine-induced experimental pancreatitis. World J Gastroenterol 2004;15:2003–2009. [PubMed: 15237423]
- Dawra R, Sharif R, Phillips P, et al. Development of a new mouse model of acute pancreatitis induced by administration of L-arginine. Am J Physiol Gastrointest Liver Physiol 2007;292:G1009–G1018. [PubMed: 17170029]
- Aho HJ, Koskensalo SM, Nevalainen TJ. Experimental pancreatitis in the rat. Sodium taurocholateinduced acute haemorrhagic pancreatitis. Scand J Gastroenterol 1980;15:411–416. [PubMed: 7433903]
- Laukkarinen JM, Van Acker GJ, Weiss ER, et al. A mouse model of acute biliary pancreatitis induced by retrograde pancreatic duct infusion of Na-taurocholate. Gut 2007;56:1590–1598. [PubMed: 17591621]
- Harell D, Orda R, Wiznitzer T, et al. Proteolytic proenzymes in the pancreas in the course of experimental bile-induced pancreatitis in the guinea pig. Digestion 1978;18:394–401. [PubMed: 750263]
- Frick TW, Hailemariam S, Heitz PU, et al. Acute hypercalcemia induces acinar cell necrosis and intraductal protein precipitation in the pancreas of cats and guinea pigs. Gastroenterology 1990;98:1675–1681. [PubMed: 1692552]
- 15. Chen, JM.; Férec, C. Trypsinogen genes: evolution. In: Cooper, DN., editor. Nature encyclopedia of the human genome. London: Macmillan; 2003. p. 645-650.
- 16. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141–145. [PubMed: 8841182]
- Teich N, Rosendahl J, Tóth M, et al. Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat 2006;27:721–730. [PubMed: 16791840]
- Witt H, Sahin-Tóth M, Landt O, et al. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet 2006;38:668–673. [PubMed: 16699518]
- Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000;25:213–216. [PubMed: 10835640]
- 20. Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet 2008;40:78–82. [PubMed: 18059268]
- 21. Sahin-Tóth M. Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J Biol Chem 2000;275:22750–22755. [PubMed: 10801865]
- Sahin-Tóth M, Tóth M. Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun 2000;278:286–289. [PubMed: 11097832]

Pancreas. Author manuscript; available in PMC 2009 August 1.

- 23. Szilágyi L, Kénesi E, Katona G, et al. Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J Biol Chem 2001;276:24574–24580. [PubMed: 11312265]
- 24. Kukor Z, Tóth M, Sahin-Tóth M. Human anionic trypsinogen. Properties of autocatalytic activation and degradation and implications in pancreatic diseases. Eur J Biochem 2003;270:2047–2058. [PubMed: 12709065]
- 25. Kukor Z, Mayerle J, Kruger B, et al. Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. J Biol Chem 2002;27721389-212396
- Lengyel Z, Pál G, Sahin-Tóth M. Affinity purification of recombinant trypsinogen using immobilized ecotin. Protein Expr Purif 1998;12:291–294. [PubMed: 9518472]
- Teich N, Le Maréchal C, Kukor Z, et al. Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat 2004;23:22–31. [PubMed: 14695529]
- 28. Várallyay E, Pál G, Patthy A, et al. Two mutations in rat trypsin confer resistance against autolysis. Biochem Biophys Res Commun 1998;243:56–60. [PubMed: 9473479]
- 29. Kukor Z, Tóth M, Pál G, et al. Human cationic trypsinogen. Arg¹¹⁷ is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. J Biol Chem 2002;277:6111–6117. [PubMed: 11748242]
- Mallory PA, Travis J. Human pancreatic enzymes. Characterization of anionic human trypsin. Biochemistry 1973;12:2847–2851. [PubMed: 4719121]
- 31. Colomb E, Guy O, Deprez P, et al. The two human trypsinogens: catalytic properties of the corresponding trypsins. Biochim Biophys Acta 1978;525:186–193. [PubMed: 28765]
- 32. Hood L, Rowen L, Koop BF. Human and mouse T-cell receptor loci: Genomics, evolution, diversity, and serendipity. Ann NY Acad Sci 1995;758:390–412. [PubMed: 7625706]
- Wang K, Gan L, Lee I, et al. Isolation and characterization of the chicken trypsinogen gene family. Biochem J 1995;307:471–479. [PubMed: 7733885]
- Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996;272:1755–1762. [PubMed: 8650574]
- Glusman G, Rowen L, Lee I, et al. Comparative genomics of the human and mouse T cell receptor loci. Immunity 2001;15:337–349. [PubMed: 11567625]
- Roach JC, Wang K, Gan L, et al. The molecular evolution of the vertebrate trypsinogens. J Mol Evol 1997;45:640–652. [PubMed: 9419241]

				1														т								
TAC	ATC	GCC	ACC	ATG	AAC	GCA	CTC	CTG	ATC	CTA	GCC	CTT	GTG	GGA	GCT	GCT	GTT	GCC	TTG	CCC	ATT	GAC	GAT	GAT	GAC	AAG
				MET	Asn	Ala	Leu	Leu	Ile	Leu	Ala	Leu	Val	Gly	Ala	Ala	Val	Ala	Leu	Pro	Ile	Asp	Asp	Asp	Asp	Lys
24																										
ATC	GTT	GGG	GGC	TAT	ACC	TGC	TCG	GCA	CAC	TCC	GTT	CCC	TAC	CAG	GTG	TCC	CTG	AAC	AGT	GGC	TAC	CAC	TTC	TGC	GGC	GGC
Ile	Val	Gly	Gly	Tyr	Thr	Cys	Ser	Ala	His	Ser	Val	${\tt Pro}$	Tyr	Gln	Val	Ser	Leu	Asn	Ser	Gly	Tyr	His	Phe	Cys	Gly	Gly
51																										
TCC	CTC	ATC	AAT	AAC	CAA	TGG	GTG	GTG	TCT	GCG	GCT	CAC	TGC	TAC	AAG	TCT	CAG	ATC	CAA	GTG	AGA	CTG	GGA	GAG	CAC	AAC
Ser	Leu	Ile	Asn	Asn	Gln	Trp	Val	Val	Ser	Ala	Ala	His	Cys	Tyr	Lys	Ser	Gln	Ile	Gln	Val	Arg	Leu	Gly	Glu	His	Asn
78														G							C	GP2 s	sense	e pri	mer	
ATC	AAA	GTC	TCG	GAG	GGG	AGT	GAA	CAA	TTT	ATC	ACT	GCA	AGC	AAA	ATC	ATC	CGT	CAT	CCC	AGC	TAC	AGC	AGC	AGC	ACC	CTG
Ile	Lys	Val	Ser	Glu	Gly	Ser	Glu	Gln	Phe	Ile	Thr	Ala	Ser	Lys	Ile	Ile	Arg	His	${\tt Pro}$	Ser	Tyr	Ser	Ser	Ser	Thr	Leu
105																	122									
AAC	AAT	GAC	ATC	ATG	CTG	ATC	AAG	CTC	GCC	TCA	GCT	GCA	AAC	CTC	AAC	TCC	AAA	GTG	GCC	GCT	GTA	TCT	CTG	CCC	TCC	TCC
Asn	Asn	Asp	Ile	Met	Leu	Ile	Lys	Leu	Ala	Ser	Ala	Ala	Asn	Leu	Asn	Ser	Lys	Val	Ala	Ala	Val	Ser	Leu	Pro	Ser	Ser
132																										
TGT	GTG	TCT	GCT	GGC	ACC	ACA	TGT	CTC	ATC	TCT	GGC	TGG	GGC	AAC	ACT	CTG	AGC	TCT	GGA	GTC	AAA	AAC	CCA	GAC	CTG	CTG
Cys	Val	Ser	Ala	Gly	Thr	Thr	Cys	Leu	Ile	Ser	Gly	Trp	Gly	Asn	Thr	Leu	Ser	Ser	Gly	Val	Lys	Asn	Pro	Asp	Leu	Leu
159														GP2	anti	isens	se pi	rime	2							
CAG	TGC	CTG	AAT	GCT	CCT	GTG	CTT	AGT	CAG	TCT	TCG	TGT	CAG	TCC	GCC	TAT	CCT	GGA	CAG	ATC	ACC	AGC	AAC	ATG	ATC	TGC
Gln	Cys	Leu	Asn	Ala	Pro	Val	Leu	Ser	Gln	Ser	Ser	Cys	Gln	Ser	Ala	Tyr	Pro	Gly	Gln	Ile	Thr	Ser	Asn	Met	Ile	Cys
186											GP1	l sei	nse a	and a	antis	sense	e pri	mers	5							
GTT	GGC	TAC	CTC	GAG	GGA	GGC	AAG	GAT	TCT	TGC	CAG	GGT	GAC	TCT	GGT	GGC	CCT	GTG	GTC	TGC	AAT	GGG	CAA	CTC	CAG	GGC
Val	Gly	Tyr	Leu	Glu	Gly	Gly	Lys	Asp	Ser	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Val	Val	Cys	Asn	Gly	Gln	Leu	Gln	Gly
213																										
GTT	GTC	TCC	TGG	GGT	TAT	GGC	TGT	GCT	CAG	AAA	AAC	AAG	CCT	GGA	GTG	TAT	ACC	AAG	GTG	TGC	AAC	TAC	GTG	TCC	TGG	ATT
Val	Val	Ser	Trp	Gly	Tyr	Gly	Cys	Ala	Gln	Lys	Asn	Lys	Pro	Gly	Val	Tyr	Thr	Lys	Val	Cys	Asn	Tyr	Val	Ser	\mathtt{Trp}	Ile
240						246																				
CGA	CAG	ACC	ATC	GCT	AGT	AAC	TGA	GCC	CCT	AGT	CCT	GCT	GCC	ATC	CCT	ATG	CCA	ATA	AAG	TGA	TCT	GTG	CTT	G		
Arg	Gln	Thr	Ile	Ala	Ser	Asn	STO	2																		

Figure 1.

Complementary DNA and deduced amino acid sequence of guinea pig pre-trypsinogens. Amino-acid numbering starts with the initiator methionine codon. Isoform 1 is shown, with the nucleotide differences present in isoform 2 indicated by superscripts. Note that Ala15 becomes Ser15 in isoform 2, whereas Lys92 remains unchanged. The sequences where the GP1 and GP2 primers anneal are underlined. The activation peptide is highlighted in gray.





Figure 2.

Purification of the guinea pig trypsinogen. (A) Mono S ion-exchange chromatography of the guinea pig trypsinogens eluted from the ecotin affinity column. See text for details. The Mono S column was developed with a 0–0.5 M gradient of NaCl at a flow rate of 1 mL/min. (B) SDS-PAGE analysis of the ecotin-eluate (E, 50 μ L loaded; ~15 μ g protein) and Mono S peaks 1 and 2 (100 μ L from the 1 mL fraction loaded; ~15 μ g protein). Samples were precipitated with trichloroacetic acid (10 % final concentration); solubilized in reducing Laemmli sample buffer, heat-denatured, electrophoresed on 13 % minigels, and stained with Coomassie blue. MultiMark multi-colored standards (Invitrogen) were used as molecular weight markers (M).



Figure 3.

Activation of trypsinogen by enteropeptidase. (A) 2 μ M (final concentration) of guinea pig trypsinogen (open circles) and human cationic trypsinogen (solid squares) were incubated with 28 ng/mL enteropeptidase (final concentration) at 37 °C, in 0.1 M Tris-HCl (pH 8.0), 2 mg/ mL bovine serum albumin and 1 mM CaCl₂ in a final volume of 100 μ L. Aliquots of 2 μ l were withdrawn from reaction mixtures at the indicated times, and trypsin activity was determined with the synthetic substrate *N*-CBZ-Gly-Pro-Arg-*p*-nitroanilide. Trypsin activity was expressed as a percentage of full activity. (B) Samples (100 μ L) were precipitated with 10 % trichloroacetic acid (final concentration) at the indicated times and analyzed by reducing SDS/PAGE (13%) and Coomassie Blue staining.

Pancreas. Author manuscript; available in PMC 2009 August 1.



Figure 4.

Activation of trypsinogen by cathepsin B. Guinea pig trypsinogen (open circles) and human cationic trypsinogen (solid squares) were activated at 2 μ M concentration with human cathepsin B (90 μ g/mL) at 37 °C in 0.1 M sodium acetate buffer (pH 4.0) in the presence of 1 mM dithiothreitol, 2 mg/mL bovine serum albumin, 1 mM K-EDTA and 0.3 mM benzamidine. Aliquots (2 μ L) were withdrawn at indicated times and trypsin activity was measured on the synthetic substrate.



Figure 5.

Trypsin-mediated trypsinogen activation (autoactivation). Guinea pig trypsinogen (open circles), human cationic trypsinogen (solid squares) and human anionic trypsinogen (solid triangels) were activated with their respective trypsins. The reactions were carried out at 37 ° C, using 2 μ M trypsinogen, 1 mM CaCl₂, 0.1 M Tris-HCl (pH 8.0), and 200 nM trypsin initial concentrations. Although not shown, increasing the CaCl₂ concentration to 10 mM had no measurable stimulatory effect on the autoactivation of guinea pig trypsinogen in this time range.



Figure 6.

Autocatalytic degradation (autolysis) of trypsin. Guinea pig trypsinogen (open circles), human cationic trypsinogen (solid squares), and human anionic trypsinogen (solid triangles) were activated at 2 μ M concentration with enteropeptidase for 60 min at 37 °C in the presence of 1 mM CaCl₂. Autocatalytic inactivation of trypsins was then followed at 37 °C after addition of K-EDTA (pH 8.0) to a final concentration of 2 mM. Residual activities were expressed as percentage of the full trypsin activity measured after enteropeptidase activation.

Table 1

Kinetic parameters of guinea pig trypsin and human cationic trypsin on the synthetic substrate *N*-CBZ-Gly-Pro-Arg-*p*-nitroanilide.

	$\mathbf{k}_{cat} (s^{-1})$	$K_{M}\left(\mu M\right)$	$k_{cat}/K_{M}(M^{-1} {\cdot} s^{-1})$
guinea pig	115.6	14.6	$7.9 imes 10^6$
human cationic	85.3	17.6	$4.8 imes 10^6$